US 8828356
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
granted A61KA61K31/4545A61K31/4709
Quick answer
US patent 8828356 (Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/4545, A61K31/4709, A61K45/06, A61P